Veradermics reports 12‑month Phase 2/3 hair‑loss trial results, shares climb
Veradermics Inc released 12‑month data from Part B of its Phase 2/3 Study 302 in 519 men with mild‑to‑moderate pattern hair loss. The twice‑daily dose increased non‑vellus hair count by 43.9 hairs per cm², while the once‑daily dose added 29.7 hairs per cm², and the treatment was well tolerated. The results lifted the stock and prompted Leerink Partners to raise its price target.
Why it matters
The company says the data position VDPHL01 as a potential first FDA‑approved oral pill for pattern hair loss in nearly three decades, which could drive future revenue. Leerink Partners raised its target to $150, indicating analysts expect a higher valuation.
Key facts
- 1The Phase 2/3 Study 302 Part B enrolled 519 men with mild‑to‑moderate pattern hair loss. investing.com
- 2Twice‑daily dosing produced a non‑vellus hair count increase of 43.9 hairs/cm² from baseline at month 12. tradingview.com
- 3Once‑daily dosing produced a gain of 29.7 hairs/cm² at month 12. tradingview.com
- 4Leerink Partners raised its price target for Veradermics to $150 from $135. investing.com
- 5Veradermics plans to announce data from its female pattern hair loss study in the first half of 2027. investing.com
Open questions
- Material 2 reports a 2.3% stock rise, while material 3 reports a 2.5% rise.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.